Medistep Healthcare
- Market cap
- ₹ 30 Cr.
- P/E
- 4.5x
- P/B
- 0.8x
- 52-week range
- 16.5 – 30
- ROE
- 22%
- ROCE
- 27%
- Dividend yield
- 0%
- Debt / equity
- 0.14
- Sector
- Personal Products
- Industry
- Personal Care
- Listed on
- NSE SME
About
Medistep healthcare Limited is an India-based pharmaceutical company. The Company is primarily engaged in the business of manufacturing sanitary pads, energy powder and trading a diverse range of pharmaceutical products. It is also engaged in trading and distribution of pharmaceutical, nutraceutical, surgical and intimate Care Products. Its manufacturing products include Intimate Care and Hygeine Products (Drystep Sanitary Pad) and Nutraceuticals Products (Vitastep-Z Energy Powder). It is also focused he business of manufacturing and distribution, wholesale and retail trade of all kinds of pharmaceuticals including controlled drugs, active pharmaceutical ingredient (API), antibiotics, drugs, medicine, biologicals, nutraceuticals, organic, food items, healthcare, ayurvedic and dietary supplement products, medicinal preparations, vaccines, among others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Personal Care: 22 companies →Medistep Healthcare against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)4.5 against a typical 33.9: cheaper than most peers (1st = cheapest).1st of 22
- Share price, 3 months−2.6% against a typical −7.5%.8th of 19
- Size₹ 30.4 Cr. market value against a typical ₹ 188.1 Cr. (1st = largest).16th of 19
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 2 Nov 2026Upcoming | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2026 and other business matters |
| 30 May 2026 | Financial Results | MEDISTEP : 30-May-2026 : The Company has informed the Exchange that a Board meeting to be held on May 26, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on May 30, 2026, To consider and approve the financial results for the period ended March 31, 2026 |
| 26 May 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2026 and other business matters |
| 11 Nov 2025 | Financial Results/Other business matters | To consider and approve the financial results for the Half Year ended September 30, 2025 and other business matters |
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 21 | 28 | 35 | 36 |
| Expenses | 19 | 25 | 31 | 31 |
| Operating Profit | 2 | 3 | 4 | 4 |
| OPM % | 10.8% | 11.7% | 11.4% | 11.9% |
| Other Income | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 |
| Profit before tax | 2 | 3 | 4 | 4 |
| Tax % | 25.3% | 25.3% | 25.2% | 25.1% |
| Net Profit | 2 | 2 | 3 | 3 |
| EPS in Rs | 1.61 | 2.35 | 2.09 | 2.12 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- 43%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- 44%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 24%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Medistep Healthcare | ₹ 18.75 | ₹ 30 Cr. | 4.5x | 0.8x | 22% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 35x | 5.1x | — | 19.8% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 94.7x | 14.8x | — | 26.1% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 70.5x | 18.6x | — | 13.7% |
| Laurus Labs | ₹ 1,974.00 | ₹ 1,08,738 Cr. | 120.8x | 20.4x | — | 15% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 25.4x | 3.1x | — | 11.9% |
Management
- Jagdish Prajapati
- Chief Financial Officer
- Sashi Kala Bhutra
- Company Secretary, Compliance Officer
- Girdhari Lal Prajapat
- Managing Director, Executive Director
- Dabhi Vipul Gobarbhai
- Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.